Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1.
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
Daclizumab for relapsing remitting multiple sclerosis.
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
Sanofi withdraws Campath in US and EU
Imaging Neurodegeneration and Repair in Multiple Sclerosis
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.
Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
The two faces of neuromyelitis optica.
Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
SIRT1 deacetylates RORγt and enhances Th17 cell generation.
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Biogen Reports Another Tecfidera PML Case
Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand.
Cladribine
Race to Erase MS Forum and Expo
Symptom changes in multiple sclerosis following psychological interventions: a systematic review.

Pages